In 1867 Bezold and Bloebaum showed in animals that, after atropine, stimulating the vagus no longer slowed the heart, and placed the effect in an end organ within the heart.
Reading Library · Anesthesia Epochs · 中文版
Watch the education video (for clinicians)
1867: Bezold and Bloebaum on Atropine — Where the Slowing Was Lost · Anesthesia Epochs Education Series

A modern conceptual image separates a thread from an interrupted shadow. It is not a nerve diagram, electrical circuit or reconstruction of the apparatus.
A stimulus that no longer slowed the heart did not, by itself, reveal where the response had failed.
In their 1867 account of atropine sulfate, A. von Bezold and Friedr. Bloebaum asked how the change occurred. Had an influence in the brain altered? Had the nerve lost excitability along its course? Or had something within the heart ceased to respond to its inhibitory action? [1, pp. 35, 39]
The drug effect became a problem of location. Counting established a change; comparisons helped constrain its explanation.
Earlier experiments inside an 1867 publication
The introduction dates the experiments to the winter semester of 1865–1866. It points to two preliminary reports in the Neue Würzburger Zeitung of 12 February and 16 May 1866, then describes a Latin dissertation by the other author and further recent experiments. [1, p. 3]
The year in this article is the year printed on the title page of the volume’s first part. It is not an exact day on which the entire discovery occurred. The newspaper items and dissertation have not been independently read here; their mention does not turn them into three additional verified sources.

Modern editorial cards mark 1865–1866, 1866 and 1867: the experimental period, preliminary reports and detailed publication. They are not reproductions of historical documents or exact experiment dates.
More than one explanation for a faster heart
The authors principally used rabbits, with some experiments in dogs. They counted heartbeats with a stethoscope or the movement of a Middeldorff needle and measured arterial pressure. These were animal physiological experiments, not modern electrocardiograms or trials of prophylaxis in surgical patients. [1, p. 28]
Several mechanisms might increase the rate. The discussion considered loss of vagal influence, activity of accelerating nerves, changes within the heart and other factors. It also acknowledged Botkin’s earlier observation that large doses could abolish vagal action. The difficulty, the authors argued, was that other motor nerves had also become ineffective, leaving the site of action uncertain. [1, pp. 34–35]
This is their account and criticism of a predecessor. Botkin’s original was not examined for this essay. The passage cautions against a simple claim of “first,” without settling the priority of every relevant investigation.
Remove an influence, then add the drug
The paper proposed three routes: divide the cervical vagus before giving atropine, stimulate the peripheral nerve ends after giving it, and examine the influence of the nerve’s origins in the brain. This essay follows the first two within the pages read here. [1, p. 35]
The first comparison asked whether atropine would produce the same marked acceleration after the existing vagal influence had been removed. The authors summarized the result as a loss of that striking increase; the rate instead tended to fall after injection. Comparing this with the response when the vagus remained intact supported their interpretation that the drug removed an existing inhibitory influence. [1, pp. 38–39]
That interpretation belonged to the animals and conditions described. It did not establish an invariant response across doses, species and clinical settings.
Fifteen-second counts and a changing response
The stimulation experiments preserved a more detailed sequence. In one dog, an initial count of eighteen beats in fifteen seconds rose to forty-two in the same interval after administration. The right vagus was then divided and stimulated electrically. Under some stimulus conditions, the heart no longer slowed. [1, pp. 39–40]
The response was not uniformly absent from the outset. Stronger stimulation still briefly reduced the count from forty-five to thirty-five; that slowing disappeared after about fifteen seconds. After preparation and division of the left nerve, the authors reported that even their strongest stimulation no longer slowed the heart. At most six to seven minutes had passed since administration. [1, p. 40]
The eighteen and forty-two were counts per fifteen seconds, not per minute. The intermediate response also matters. Omitting it would turn a developing effect into an immediate, complete loss that the sequence does not describe.

Modern editorial cards retain “15 s,” “18” and “42” from this one experiment. They are not an ECG, continuous time series, group average or clinical target.
Locating an effect without seeing a receptor
On page 41, the authors emphasized the preservation of other motor, sensory or vascular nerve responses when cardiac vagal action was already absent. They inferred that atropine acted on a special end organ within the heart, distinct from the nerve fiber itself. [1, p. 41]
Their end organ was an interpretation drawn from functional differences. It should not be rewritten as direct visualization of a new anatomical structure, receptor isolation or proof of a modern molecular mechanism. The argument narrowed a broad statement that a nerve no longer worked into a question about where the effect occurred.

Two blank sheets and a glass object form a modern editorial still life. They contain no invented measurements, tissue specimen or quotation from the original.
The paper also described falling pressure, weakened heart action and arrest with stronger toxic exposures. [1, pp. 34, 56] It cannot therefore be reduced to an assertion that atropine only accelerates the heart, or used by itself to establish clinical safety or prevention of chloroform accidents. The critical pages read here do not establish the latter connection.
The report preserves a particular way of reasoning: alter a pathway, apply a stimulus and compare which responses remain. The drug became both something to explain and a means of asking where a physiological effect took place.
Sources and reading limits
[1] Bezold A von, Bloebaum Friedr. Ueber die physiologischen Wirkungen des schwefelsauren Atropin’s. In: Untersuchungen aus dem physiologischen Laboratorium in Würzburg. Erster Theil. Leipzig: Wilhelm Engelmann; 1867:1–72. Original-edition scan.
Read: the volume title, contents, article title and printed pp. 3, 28, 34–35, 38–41, 56 and 72.
Not covered: the rest of the seventy-two-page article and of the volume; the referenced plates.
Source limits: the 1866 reports, Bloebaum’s dissertation and Botkin’s original are known here through this paper’s references, not independent examination. The dose unit in experiment II on page 40 raises a discrepancy with the surrounding summary; that value is neither adopted nor silently corrected. A chloroform connection, global priority and clinical prevention are not claimed here. Experimental counts are not dosing advice. All four images are original interpretive works.
Continue exploring
Related reading connects shared questions and contexts; it does not by itself establish historical influence.
- 1831: Mein's Crystalline Atropine, a Sample Before the Paper
- 1856: Bernard Shows Curare Paralyses Movement but Not Feeling
Anesthesia Epochs · The Source Room · About & Editorial Method
Updated October 30, 2026. Sources and reading limits are stated above. Illustrations are labelled as original source images or AI-made. Historical accounts are educational; they are not current treatment instructions.